Home Newsfeeds Culper Research Says Is Short Xometry

Culper Research Says Is Short Xometry

https://twitter.com/CulperResearch/status/1617894150367752198

January 24, 2023

1 minute read

We are short Xometry, Inc. ($XMTR). Our full report is now available on our website https://t.co/4MDshx694r

— Culper (@CulperResearch) January 24, 2023

Canopy Growth Stock Plunges In Pre-Market On Trying To Raise $50M To Strengthen Finances

By Nina Zdinjak

September 18, 9:10 AM

Canadian cannabis giant Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) entered Monday into subscription agreements with certain institutional investors in a private placement offering of 22.93 million units at a price of $1.09 per unit.

CGC

News

Consensus Cloud Solutions, Inc. Announces Receipt Of Notice From Nasdaq Regarding Late Filing Of Annual Report On Form 10-K

By Happy Mohamed

March 27, 4:03 PM

Consensus Cloud Solutions, Inc. (NASDAQ:CCSI) announced today that in connection with its previously announced delay in filing its Annual Report on Form 10-K for the year ended December 31, 2022 (the "Form

CCSI

Morgan Stanley Maintains Underweight on Saia, Lowers Price Target to $185

By Benzinga Newsdesk

October 3, 9:51 AM

Morgan Stanley analyst Ravi Shanker maintains Saia (NASDAQ:SAIA) with a Underweight and lowers the price target from $195 to $185.

SAIA

Candel Therapeutics Announces Oral Presentation During The 5th Glioblastoma Drug Development Summit With Update On Phase 1b Clinical Trial Of CAN-3110 In Recurrent High-Grade Glioma; Expects To Initiate Investigational New Drug-Enabling Work In A Secon…

By Benzinga Newsdesk

March 28, 4:17 PM

The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial. The serial procedures were well tolerated without observed dose-limiting toxicity. A second

CADL

Culper Research Says Is Short Xometry

Related Posts

Canopy Growth Stock Plunges In Pre-Market On Trying To Raise $50M To Strengthen Finances

Consensus Cloud Solutions, Inc. Announces Receipt Of Notice From Nasdaq Regarding Late Filing Of Annual Report On Form 10-K

Morgan Stanley Maintains Underweight on Saia, Lowers Price Target to $185

Candel Therapeutics Announces Oral Presentation During The 5th Glioblastoma Drug Development Summit With Update On Phase 1b Clinical Trial Of CAN-3110 In Recurrent High-Grade Glioma; Expects To Initiate Investigational New Drug-Enabling Work In A Secon…